Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
KMS MedisurgiBOM:540468 79 Return-on-Tangible-Equity is 0.34% as of Mar. 2026, which is 89% below its 10-year median of 3.14. GuruFocus rates BOM:540468 with a GF Score™ of 79/100 and a GF Value™ of ₹111.50 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 759 Medical Devices & Instruments companies, KMS Medisurgi ranks worse than 52.57% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. KMS Medisurgi's annualized net income for the quarter that ended in Mar. 2026 was ₹0.3 Mil. KMS Medisurgi's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹83.2 Mil. Therefore, KMS Medisurgi's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 0.34%.
The historical rank and industry rank for KMS Medisurgi's Return-on-Tangible-Equity or its related term are showing as below:
BOM:540468'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 1.78 Med: 3.14 Max: 8.25
Current: 2.98
During the past 13 years, KMS Medisurgi's highest Return-on-Tangible-Equity was 8.25%. The lowest was 1.78%. And the median was 3.14%.
BOM:540468's Return-on-Tangible-Equity is ranked worse than 52.57% of 759
companies
in the Medical Devices & Instruments industry
Industry Median: 4.04
vs BOM:540468: 2.98
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
KMS Medisurgi Return-on-Tangible-Equity Related Terms
KMS Medisurgi Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for KMS Medisurgi's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:540468 vs ISRG, BDX, MDLN: Return-on-Tangible-Equity Comparison
For the Medical Instruments & Supplies subindustry, KMS Medisurgi's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
KMS Medisurgi Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, KMS Medisurgi's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where KMS Medisurgi's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 0.34% mean?
KMS Medisurgi (BOM:540468) has a Return-on-Tangible-Equity of 0.34% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on KMS Medisurgi and its competitors. This is 89% below median its historical median of 3.14. Over the past decade, KMS Medisurgi's Return-on-Tangible-Equity has ranged from 1.78 to 8.25. According to the industry distribution chart, KMS Medisurgi ranks #399 out of 759 companies in the Medical Devices & Instruments industry, placing it in the top 52.6%.
Is KMS Medisurgi's Return-on-Tangible-Equity too high?
KMS Medisurgi's current Return-on-Tangible-Equity of 0.34% is 89% below median its 10-year median of 3.14. Over the past 10 years, this metric has ranged from a low of 1.78 to a high of 8.25. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.04. KMS Medisurgi's value of 0.34% is 91.6% below this industry median. Based on the distribution chart, KMS Medisurgi ranks #399 out of 759 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, KMS Medisurgi has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does KMS Medisurgi's Return-on-Tangible-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, KMS Medisurgi ranks #399 out of 759 companies for Return-on-Tangible-Equity. This places KMS Medisurgi in the lower half of its industry. The industry median Return-on-Tangible-Equity is 4.04. KMS Medisurgi's value of 0.34% is 91.6% below this benchmark. Historically, KMS Medisurgi's own Return-on-Tangible-Equity has ranged from 1.78 to 8.25 over the past decade. While the company's 10-year median is 3.14 vs. the industry median of 4.04, KMS Medisurgi has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.04, based on 759 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. KMS Medisurgi's current Return-on-Tangible-Equity of 0.34% is 91.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on KMS Medisurgi and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. KMS Medisurgi's current Return-on-Tangible-Equity is 0.34%, which is 89% below median its own 10-year median of 3.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is KMS Medisurgi stock overvalued right now?
Based on GuruFocus' analysis, KMS Medisurgi (BOM:540468) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹111.50, compared to a current price of ₹132.80 — trading 19.1% above its estimated fair value. The current Return-on-Tangible-Equity is 0.34%, which is 89% below median its 10-year median of 3.14 and 91.6% below the Medical Devices & Instruments industry median of 4.04. KMS Medisurgi's overall GF Score™ is 79/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For KMS Medisurgi (BOM:540468), the current Return-on-Tangible-Equity is 0.34% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is KMS Medisurgi (BOM:540468) Overvalued in 2026?
Based on GuruFocus' analysis, KMS Medisurgi stock appears to be overvalued.
The current stock price of ₹132.80 is trading 19.1% above its estimated GF Value™ of ₹111.50.
GuruFocus considers KMS Medisurgi to be Modestly Overvalued.
Key valuation signals for BOM:540468:
Return-on-Tangible-Equity: 0.34% (89% below median its 10-year median of 3.14)
GF Value™: ₹111.50 vs. price of ₹132.80 (19.1% above fair value)
Industry Position: 91.6% below the Medical Devices & Instruments median (#399 of 759)
No single metric tells the full story. See the BOM:540468 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
KMS Medisurgi Ltd manufactures surgical tapes and dressings for hospitals, institutions, trade associations, exporters, and importers. The company manufactures and undertakes job work of various substartes like non-woven fabrics, PU films, cotton fabrics, and taffeta silk fabrics with adhesive. The company's international presence includes Vietnam, Dubai, Europe, Australia, Cambodia, India, Africa, Philippines, Russia, Pakistan, Bangladesh, and the USA. The company derives revenue from the sale of goods.
79GF Score
Get the complete analysis for BOM:540468
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540468 has been successfully added to your 
